| Name | Title | Contact Details |
|---|---|---|
Frederic Dross |
Vice President of Technology Americas | Profile |
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.
OMICS Group Inc is a Henderson, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system.
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing`s Syndrome (CS).
Seisa Medical is a El Paso, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.